Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 alone or HLX43 + HLX07 versus docetaxel in previously treated advanced or metastatic squamous NSCLC
CTR20260810Phase 3Active
- Sponsor
- HyBioPharma
- Start
- May 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HLX43, pimurutamab, docetaxel in Pulmonary squamous cell carcinoma, sponsored by HyBioPharma. Started May 2026; status: active.
02
Drugs
HLX43pimurutamabdocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20260810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260810.